Rabbit anti-extracellular signal-regulated kinases 1/2 (ERK1/2; #9102), rabbit anti-interleukin-1 beta (IL-1β; #31202), rabbit anti-IL-6 (#12912), rabbit anti-phospho (p)-ERK1/2 (#9101), rabbit anti-c-Jun N-terminal kinases (JNK; #9258), rabbit anti-p-JNK (#4668), rabbit anti-NF-kappa-B inhibitor alpha (IκB-α; #4814), rabbit anti-p-IκB-α (#2859), rabbit anti-pro-caspase-3 (#9662), rabbit anti-cleaved caspase-3 (#9661), rabbit anti-p38 mitogen-activated protein kinase (MAPK; #9212), mouse anti-p-p38 MAPK (#9216), and rabbit anti-transforming growth factor-beta (TGF-β; #3711) antibodies were purchased from Cell Signaling Technology (Danvers, MA, United States). Mouse anti-arginase-1 (Arg-1; #sc-271430), mouse anti-IL-10 (#sc-8438), rabbit anti-nuclear factor erythroid 2-related factor 2 (Nrf2; #sc-365949), mouse anti-β-actin (#sc-47778), rabbit anti-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB; #sc-7151), and rabbit anti-p-NF-κB (#sc-101752) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States). Mouse anti-cyclooxygenase-2 (COX-2; #610203), mouse anti-inducible nitric oxide synthase (iNOS; #610329), mouse anti-dopamine- and cAMP-regulated neuronal phosphoprotein-32 (DARPP-32; #611520), and rat anti-tumor necrosis factor-alpha (TNF-α; #551225) antibodies were purchased from BD Biosciences (San Jose, CA, United States). Mouse anti-heme oxygenase-1 (HO-1; #ADI-OSA-110) antibody was purchased from Invitrogen (Waltham, MA, United States). Rabbit anti-ionized calcium-binding adapter molecule 1 (Iba-1; #NCNP24) was purchased from Wako Pure Chemical (Osaka, Japan). Goat anti-4-hydroxynonenal (4-HNE; #HNE11-S) was purchased from Alpha Diagnostic International (San Antonio, TX, United States). Mouse anti-heme oxygenase-1 (HO-1; #ADI-OSA-110) was purchased from Enzo Biochem (Farmingdale, NY, United States). Rat anti-cluster of differentiation 68 (CD68; #FA-11) antibody was purchased from ALZFORUM (Madrid, Spain). MitoSOX™ Red mitochondrial superoxide indicator (#M36008) was purchased from Molecular Probes (Eugene, OR, United States). All other reagents were purchased from Sigma-Aldrich (St. Louis, MO, United States).

SSC was provided by Mungyeong-si Distribution Corporation (Mungyeong, Republic of Korea). SSC samples were ground to an average particle size of 520 μm. Commercial-grade carbon dioxide (purity 99.5%) was purchased from a local gas company (Seoul, Republic of Korea). Supercritical CO2 extraction experiments were carried out using a custom-built high-pressure extraction apparatus. Figure 1 shows a schematic of the extraction system. The apparatus consisted mainly of a high-pressure extraction vessel (6), a back-pressure regulator (9), a separator (10), a liquid CO2 storage tank (11), a high-pressure CO2 pump (4), a precooler (Landis, Amara et al.), and a preheater (5). The extraction vessel was equipped with an internal basket of 250 mL (33.5 mm inner diameter × 284 mm height). The internal basket had a bottom with porous, sintered steel plates to support feed materials. The extraction vessel was rated for a maximum pressure of 400 bar at 80°C. The separator volume was 127 mL (30 mm ID × 180 mm H). The volume of the CO2 recycle storage tank was 4,600 mL (150 mm ID × 260 mm H).

A back-pressure regulator was purchased from HIFLUX Co., Ltd. (Daejeon, Republic of Korea). It was rated for a maximum pressure of 41.3 MPa. Supercritical extraction was carried out at 10–40 MPa in a temperature range of 40°C–60°C. The temperature in the extraction vessel was controlled with an external heating jacket through which water at the desired temperature was circulated. After 50 g of ground SSC was loaded into the internal basket, the basket was aligned with the extraction vessel cover. A plunger pump (HKS-3000, Hanyang Accuracy, Republic of Korea) was used to initially fill the vessel to the desired extraction pressure and then circulate CO2 in an up-flow direction through the system. Extracts were collected at a constant flow rate of 30 mL CO2/min for 1 hour. At the end of the extraction, the weight ratio of CO2 to SSC was approximately 25. The extractor was depressurized to unload the residue.

The SOSC was standardized with schizandrin, gomisin A, and gomisin N for quality assurance. SOSC (6.0 mg) was dissolved with tetrahydrofuran (1.0 mL). Standard compounds were isolated as described in our previous study (Jeong et al., 2017). Briefly, the purity of each standard compound was confirmed to be over 98% by HPLC and nuclear magnetic resonance (NMR) analysis. Standard compounds were prepared by serial dilution of methanol (62.5, 125, 250, 500, and 1,000 μg/mL). Each solution was filtered through a 0.20 μm syringe filter (Whatman Inc., Maidstone, United Kingdom) before HPLC analysis. The analysis was performed using Waters Alliance 2,795 and Waters 996 PDA. The analysis was carried out with an analytical YMC-Triart C18 column (YMC, 150 × 4.6 mm I.D., 5 μm). Mobile phase solvents A (water contained 0.1% formic acid) and B (methanol contained 0.1% formic acid) were operated with a gradient elution at a flow rate of 0.5 mL/min as follows: 76%–77% B (0–40 min), 77%–100% B (45–50 min) and then held for 10 min before returning to initial conditions. The injection volume was 10 μL. UV detection was conducted at 254 nm. The column temperature was 25°C. The analysis was repeated three times.

Male adult C57BL/6 mice (Narabiotec Co., Ltd., Seoul, Republic of Korea; weight, 23–25 g; n = 105; Seed mice were originated from Taconic Biosciences Inc., Rensselaer, NY, United States) were kept under constant temperature (23 ± 2°C) and humidity (55 ± 5%) conditions with a 12-h light-dark cycle (light on 08:00 to 20:00), and fed food and water ad libitum. The mice were allowed to habituate to the housing facilities for 1 week before the experiments. All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee of Kyung Hee University (KHSASP-22–032). Proper randomization of mice and handling of data were performed in a blinded manner in accordance with recommendations from a NIH Workshop on preclinical models of neurological diseases (Landis et al., 2012).

The experimental group was divided into the following groups: The Sham group [saline treatment, i. p. + vehicle, p. o.], 3-NPA [3-NPA, i. p. + vehicle, p. o.], 3-NPA + SOSC75 group [3-NPA, i. p. + 75 mg/kg of SOSC, p. o.], 3-NPA + SOSC150 group [3-NPA, i. p. + 150 mg/kg of SOSC, p. o.], 3-NPA + SOSC300 group [3-NPA, i. p. + 300 mg/kg of SOSC, p. o.], and SOSC alone group [saline treatment, i. p. + 300 mg/kg of SOSC, p. o.]. 3-NPA model was induced according to the previous described (Jang and Cho, 2016; Jang et al., 2014; Jang et al., 2013; Kim et al., 2017). Briefly, 3-NPA solution was given intraperitoneally (i.p.) twice daily for 2 days at 12-h intervals (8:00 a.m. and 8:00 p.m.) at a dose of 60 mg/kg on the first day and 80 mg/kg on the second day (60–60–80–80 dose regimen). SOSC was prepared with a vehicle [1% tween 80 in phosphate-buffered saline (PBS)] and administered at different doses (75, 150, and 300 mg/kg) to determine the most effective dose. Total daily dose of SOSC for mice was determined by formula for dose translation based on body surface area (Reagan-Shaw et al., 2008) after considering body weight of animals, final extract yield, and traditional dose in humans. SOSC was administered at 1 hour before 3-NPA intoxication. Experiment was repeated at least three times using the same protocol.

The severity of neurological impairment (motor disability) induced by 3-NPA was assessed by an experimenter who was unaware of the experimental condition under constant temperature (23 ± 2°C) and humidity (55 ± 5%) in a quiet room using the behavioral scale as previously described (Choi et al., 2018; Fernagut et al., 2002; Jang and Cho, 2016; Jang et al., 2019; Jang et al., 2014; Jang et al., 2013; Jang et al., 2018; Kim et al., 2017). Briefly, mice (n = 14 per group, consisting of 2 sets of 7 mice per group) were assessed for behavioral semi-quantitative evaluation 24 h after the last (4^th) 3-NPA intoxication. The three-level (0, 1, and 2) scale was used to measure the severity of the following five items (maximal score = 10), which constituted the main motor symptoms observed: hindlimb clasping, global activity in a free-moving environment, hindlimb dystonia, truncal dystonia (kyphotic posture), and balance adjustment to a postural challenge. Standardized motor behavioral tests (pole and rotarod tests) were conducted as previously described (Choi et al., 2018; Jang et al., 2018). Briefly, mice (n = 7 per group) were assessed using the pole and rotarod tests 24 h after the first 3-NPA intoxication. For the pole test, each mouse was placed at the top of a pole with a rough surface (1 cm in diameter and 50 cm in height), positioned with its head facing upward. The time taken for the mouse to completely turn downward at the top of the pole and climb down to the floor was recorded. One hour after the pole test, each mouse was placed on a rotating rod (diameter = 4 cm) set to rotate at 16 rpm, and performance was tested for 5 min. The latency to fall off the rotarod apparatus during this time was recorded using magnetic trip plates. Mice were acclimated to both the pole and rotarod apparatuses for 5 days prior to the first test. Mice that successfully turned downward at the top of the pole and climbed down to the floor within 2 min, as well as those that remained on the rod without falling during a 5-min training session, were selected and randomly assigned to experimental groups.

To investigate the histopathological alterations of the striatum following 3-NPA intoxication, we used a previously described protocol (Jang et al., 2019; Kim et al., 2017). Briefly, 24 h after the last (4^th) 3-NPA intoxication, the mice (n = 5 per group) were anesthetized with isoflurane and then perfused intracardially with saline and iced 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4). Sequential coronal sections (30-μm thickness) were acquired from the corpus callosum throughout the entire striatum (bregma 1.40 ∼ −1.30 mm) using published method (Franklin and Paxinos, 2008). Free-floating sections were collected in an antifreeze solution (30% sucrose in PBS) and stored at −20°C. The stained sections from the level of the mid-striatum were captured using a digital camera (Olympus DP-70) and the mean level of lesion area to whole striatal area was analyzed using the NIH ImageJ program (http://rsbweb.nih.gov/ij/).

Immunofluorescence analysis was performed as previously described (Jang et al., 2019; Lee et al., 2016; Lee et al., 2018). Briefly, 24 h after the last (4^th) 3-NPA intoxication, free floating brain sections (30-μm thickness; 3 sections per brain) from all groups (n = 5 per group) were incubated with rabbit anti-cleaved caspase-3 (1:500; Cell Signaling Technology), rabbit anti-ionized calcium-binding adapter molecule (Iba)-1 (1:2,000; WAKO, Chuo-Ku, Japan), mouse anti-Nrf2 (1:1,000; Santa Cruz Biotechnology, or mouse anti-HO-1 (1:1,000), or goat anti-4-HNE (1:1,000; Alpha Diagnostic International Inc.), mouse anti-Arg-1 (1:1,000; Santa Cruz Biotechnology), mouse anti-DARPP32 (1:1,000; BD Biosciences), mouse anti-HO-1 (1:1,000; Enzo), mouse anti-interleukin-10 (IL-10; 1:1,000; Santa Cruz Biotechnology), mouse anti-Nrf2 (1:1,000; Santa Cruz Biotechnology), rabbit anti-cleaved caspase-3 (1:500; Cell Signaling Technology), rabbit anti-ERK (1:1,000; Cell Signaling Technology), rabbit anti-Iba-1 (1:500; WAKO), rabbit anti-IκB (1:1,000; Cell Signaling Technology), rabbit anti-interleukin-1 beta (IL-1β; 1:1,000; Cell Signaling Technology), rabbit anti-JNK (1:1,000; Cell Signaling Technology), rabbit anti-NF-κB p65 (1:1,000; Santa Cruz Biotechnology), rabbit anti-p38 (1:1,000; Cell Signaling Technology), rabbit anti-p-ERK (1:1,000; Cell Signaling Technology), rabbit anti-p-IκB (1:1,000; Cell Signaling Technology), rabbit anti-p-JNK (1:1,000; Cell Signaling Technology), rabbit anti-p-NF-κB p65 (1:500 Santa Cruz Biotechnology), rabbit anti-p-p38 (1:1,000; Cell Signaling Technology), rabbit anti-pro-caspase-3 (1:1,000; Cell Signaling Technology), or rat anti-CD68 (1:1,000; ALZFORUM) antibody. And region of interest of each section were captured using a confocal laser scanning microscope (Carl Zeiss LSM 5 PASCAL). And then the intensity of Iba-1 (+) cells and the number of Nrf2 (+) cells and HO-1 (+) cells per striatum were manually and blindly measured.

Western blot analysis was performed using previously published method (Jang et al., 2019; Kim et al., 2017). Briefly, 24 h after the last (4^th) 3-NPA intoxication, the striatal proteins from all groups (n = 5 per group) were incubated with primary antibodies including goat anti-4-HNE (1:1,000; Alpha Diagnostic International Inc.), mouse anti-Arg-1 (1:500; Santa Cruz Biotechnology), mouse anti-DARPP32 (1:1,000; BD Biosciences), mouse anti-HO-1 (1:1,000; Enzo), mouse anti-IL-10 (1:500; Santa Cruz Biotechnology), mouse anti-Nrf2 (1:1,000; Santa Cruz Biotechnology), rabbit anti-cleaved caspase-3 (1:500; Cell Signaling Technology), rabbit anti-ERK (1:1,000; Cell Signaling Technology), rabbit anti-Iba-1 (1:500; WAKO), rabbit anti-IκB (1:1,000; Cell Signaling Technology), rabbit anti-IL-1β (1:1,000; Cell Signaling Technology), rabbit anti-JNK (1:1,000; Cell Signaling Technology), rabbit anti-NF-κB p65 (1:1,000; Santa Cruz Biotechnology), rabbit anti-p38 (1:1,000; Cell Signaling Technology), rabbit anti-p-ERK (1:1,000; Cell Signaling Technology), rabbit anti-p-IκB (1:1,000; Cell Signaling Technology), rabbit anti-p-JNK (1:1,000; Cell Signaling Technology), rabbit anti-p-NF-κB p65 (1:500 Santa Cruz Biotechnology), rabbit anti-p-p38 (1:1,000; Cell Signaling Technology), rabbit anti-pro-caspase-3 (1:1,000; Cell Signaling Technology), rabbit anti-transforming growth factor-beta (TGF-β; 1:1,000; Cell Signaling Technology), and rat anti-CD68 (1:1,000; ALZFORUM) antibodies. For normalization of antibody signals, membranes were stripped and reprobed with antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:5,000; Cell Signaling Technology), beta-Actin (β-Actin; 1:5,000; Santa Cruz Biotechnology) and total IκB/NF-κB p65/JNK/ERK/p38 (1:1,000; Cell Signaling Technology). Data are expressed as the ratio of corresponding protein signal to GAPDH or total protein signal for each sample.

To measure the mRNA level of inflammatory factors, 24 h after the last (4^th) 3-NPA intoxication, RT-PCR analysis using the striatal lysates from all groups (n = 5 per group) was performed using PCR Master Mix as previously described (Choi et al., 2018). Expression levels of each gene were normalized to those of GAPDH. All PCR experiments were performed at least three times, and the mean ± S.E.M. values are presented unless otherwise noted. The primer sequences were as follows: interleukin (IL)-1β-5′-TTG TGG CTG TGG AGA AGC TGT-3′ and 5′-AAC GTC ACA CAC CAG CAG GTT-3′; IL-6-5′-TCC ATC CAG TTG CCT TCT TGG-3′ and 5′-CCA CGA TTT CCC AGA GAA CAT G-3′; COX-2-5′-GCA TTC TTT GCC CAG CAC TTC ACT-3′ and 5′-TTT AAG TCC ACT CCA TGG CCC AGT-3′; iNOS-5′-GGC AAA CCC AAG GTC TAG GTT-3′ and 5′-TCG CTC AAG TTC AGC TTG GT-3′; Arg-1-5′-TCA TGG AAG TGA ACC CAA CTC TTG-3′ and 5′-TCA GTC CCT GGC TTA TGG TTA CC; IL-10–5′-GTG AAG ACT TTC TTT CAA A-3′ and 5′-TGA TCA AGA TGT CAA ACT C-3′; TGF-β-5′-CTT CAG CTC CAC AGA GAA GAA CTG C-3′ and 5′-CAC GAT CAT GTT GGA CAA CTG CTC C-3′; and GAPDH-5′-AGG TCA TCC CAG AGC TGA ACG-3′ and 5′-CAC CCT GTT GCT GTA GCC GTA T-3′.

BV2 cell lines, a type of microglial cell derived from C57BL/6 mice, were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco, Waltham, MA). BV2 cells were maintained in a humidified incubator with 95% air and 5% CO2 at 37 °C. The medium was replaced every other day. The cytotoxic effects of schizandrin on BV2 cells were determined using two methods: direct counting of living and dead cells using a hemocytometer with an inverted microscope and the MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. When the cells reached a density of approximately 90%, schizandrin (40, 60, and 80 μM) was added to the cell medium. After 1 h of incubation, 3-NPA (100 μM) was added. The medium was replaced after 6 h. Cells and their cultured medium [referred to as conditioned medium (CM)] were harvested after 36 h. These cells were subjected to Western blot analysis to investigate the protein expression levels of Iba-1, p-NF-κB, and Nrf2. CM-3-NPA (CM from 3-NPA-stimulated BV2 cells) and CM-3-NPA-schizandrin (CM from 3-NPA-stimulated BV2 cells pretreated with schizandrin) were collected and used to assess the activity of SH-SY5Y cells. CM-3-NPA and CM-3-NPA-schizandrin were used to treat SH-SY5Y cells for 48 h. CM-treated SH-SY5Y cells were collected to analyze the degree of neurodegeneration (NeuN and cleaved caspase-3) via Western blot analysis. In vitro assays were repeated at least three times, with each experiment performed in triplicate.

Statistical analysis was performed using IBM SPSS Statistics version 26.0 (SPSS Inc., Chicago, United States) for Windows. Data from experiments, including behavioral tests, immunohistochemistry, Western blotting, and PCR analysis, were analyzed using the Kruskal–Wallis test (a nonparametric test) for comparisons of three or more unmatched groups. Data are presented as mean ± SEM. P-values less than 0.05 were considered statistically significant.

To determine concentrations of schizandrin, gomisin A, and gomisin N in SOSC, HPLC analysis was performed. The HPLC chromatogram of SOSC revealed a retention time (t _R) of 7.34 min for schizandrin, 10.30 min for gomisin A, and 35.69 min for gomisin N when compared to a reference standard peak (Figure 2). To quantify concentrations of the three compounds, calibration curves for each compound were established using serially diluted standard solutions ranging from 1,000 to 62.5 μg/mL. Linear regression equations for these compounds exhibited high coefficients (R² > 0.9990) of determination: Y = 447.17X - 5,340.1 (R² = 0.9995) for schizandrin, Y = 245.81X - 592.96 (R² = 0.9998) for gomisin A, and Y = 383.69X - 4,084.7 (R² = 0.9994) for gomisin N. Finally, concentrations of schizandrin, gomisin A, and gomisin N in SOSC were determined to be 54.71 ± 0.01 mg/g, 25.13 ± 0.01 mg/g, and 36.46 ± 0.01 mg/g, respectively (Figure 2).

First, we determined whether SOSC could affect movement disorder and survival rate of mice after 3-NPA-intoxication (Figure 3A). The survival rate at the end of two representative experimental sets increased to 71.4% (n = 10/14) in the 3-NPA + SOSC 300 mg/kg/day group, compared to 50.0% (n = 7/14) in the 3-NPA group (Figure 3B). Twenty-four hours after the last (4^th) intoxication of 3-NPA, mice displayed severe neurological dysfunction (score, 8.7 ± 0.8). However, mice in the 3-NPA + SOSC group displayed significantly lower neurological scores (5.4 ± 0.4 for SOSC 300 mg/kg/day groups) than those in the 3-NPA group (Figure 3C). The mean loss of BW was significantly alleviated by 3-NPA. However, it was not significantly restored by SOSC administration (Figure 3D). SOSC alone (300 mg/kg/day) administration did not significantly affect neurological score, survival rate, or BW of normal mice (Figures 3A–D). To emphasize the efficacy of SOSC on motor coordination, the pole test and rotarod test were additionally conducted. All mice in each group (n = 7 per group) survived up to the first day following 3-NPA intoxication, during which the two behavioral tests were performed (Figures 3E, F). In the pole test, the average descent time to the bottom of the pole increased in the 3-NPA group (16.1 ± 1.2 s) compared to the sham group (3.2 ± 0.2 s). However, the average descent time was reduced to 7.3 ± 1.8 s in the SOSC 300 mg/kg/day group, compared to 16.1 ± 1.2 s in the 3-NPA group (Figure 3E). In the rotarod test, the average latency to fall decreased in the 3-NPA group (50.4 ± 3.6 s) compared to the sham group (287.0 ± 4.9 s). However, the average latency improved to 141.2 ± 14.8 s in the SOSC 300 mg/kg/day group compared to that in the 3-NPA group (Figure 3F). SOSC alone (300 mg/kg/day) administration did not significantly affect the pole test and rotarod test of normal mice (Figures 3E, F).

3-NPA produces striatal neurodegeneration and some neurological disturbances known to be characteristics of Huntington’s disease in rodents and primates (Brouillet et al., 2005; Tunez et al., 2010; Upadhayay et al., 2023). Thus, we explored whether SOSC could ameliorate striatal neurodegeneration by 3-NPA-intoxication. Twenty-four hours after the last (4^th) 3-NPA-intoxication, coronal cryo-sections of brain (n = 5 group) including the striatum were stained with cresyl violet dye. Figure 4A shows representative striatal images from sham, 3-NPA, 3-NPA + SOSC (75, 150, and 300 mg/kg/day), and SOSC alone (300 mg/kg/day) groups. The 3-NPA-treated group exhibited visible bilateral striatal lesions (pale areas surrounded by dotted line), whereas treatment with SOSC resulted in smaller lesions in a dose-dependent manner (Figure 4A). Results of quantification revealed that the ratio of mean lesion area to the entire striatum was 73.2% in the 3-NPA group, while this ratio was reduced by SOSC in dose-dependent manner to 56.4%, 37.6%, and 21.8% in the group administered with SOSC at 75, 15, and 300 mg/kg/day, respectively (Figure 4C). Based on results from cresyl violet staining (Figures 4A, C), to further compare levels of neurodegeneration, striatal lysates of all groups were subjected to Western blot assay with DARPP32 antiserum (a marker for medium spiny neurons of the striatum) (Ivkovic et al., 1997) (Figures 4B, E, F). Protein expression of DARPP32 was clearly decreased to 62.6 ± 3.3 in the 3-NPA group compared with the Sham group (188.6 ± 19.4), whereas its expression was significantly restored to 147.5 ± 23.4 in the 300 mg/kg/day SOSC-administered 3-NPA group (Figures 4E, F). To test whether the anti-neurodegenerative effect of SOSC might be related to apoptosis, we investigated the immunoreactive level of cleaved caspase-3 (a representative apoptosis marker) in the striatum by immunofluorescence staining (Figures 4B–D). Cleaved caspase-3 immunoreactivity was increased in the 3-NPA group than that in the sham group. However, its immunoreactivity was decreased by SOSC (at 75, 15, and 300 mg/kg/day) in a dose-dependent manner (Figures 4B, D). The expression pattern of cleaved caspase-3 was similar to that of cleaved caspase-3 based on Western blot (Figures 4E, G). Since administration with 300 mg/kg/day of SOSC was the most effects on behavioral dysfunction (Figure 3B), survival rate (Figure 3C), and striatal neurodegeneration (Figures 4A–G) following 3-NPA-intoxication, this dose of SOSC was used in further studies.

Microglia can migrate into/around/within lesions of brain with neurodegenerative diseases including HD (Deczkowska et al., 2018; Gao et al., 2023; Kumari and Gensel, 2023). They become activated following exposure to pathogen-associated molecular patterns (PAMPs), endogenous damage-associated molecular patterns (DAMPs), and removal of immune-suppressive signals. Activated microglia can acquire different phenotypes (pro- and anti-inflammatory) depending on cues in its surrounding environment (Deczkowska et al., 2018; Gao et al., 2023; Kumari and Gensel, 2023). Thus, we investigated whether SOSC could inhibit microglial activation in striatal lesions from all groups (n = 5 per group) after 3-NPA-intoxication (Figures 5A–D). In striatal sections of the 3-NPA group, Iba-1 (a marker for microglia/macrophage lineage cells)-immunoreactive cells revealed morphology of the activated type with bigger cell bodies and extended (short and thick) processes than those in the sham group, which displayed typical forms of resting cells including relatively small soma and long thin processes (Deczkowska et al., 2018; Gao et al., 2023; Kumari and Gensel, 2023) (Figures 5A–C). However, the mean level of Iba-1-immunoreactive cells to total striatal area was remarkably reduced in striatal sections of the 3-NPA + SOSC group than in the 3-NPA group (Figures 5A, B), in agreement with altered protein expression of Iba-1 (by 251.3% in the 3-NPA group; by 215.6%, 128.3%, and 83.5% in 75, 150, and 300 mg/kg SOSC groups, respectively) based on Western blot analysis (Figure 5C). The normal morphology of Iba-1 immunoreactive cells based on immunofluorescence and normal Iba-1 protein expression based on Western blot analysis were not significantly affected by administration with SOSC (300 mg/kg/day) alone (Figures 5A–D). These findings suggest that SOSC might inhibit microglial migration and activation. Such inhibition is closely associated with reduction of striatal cell death and mitigation of neurological impairment following 3-NPA-intoxication.

Activated microglia around (or within) CNS lesions can secrete pro- or anti-inflammatory enzymes and cytokines that are either beneficial or detrimental to neuronal survival and cell death signaling pathways (Ferger et al., 2010; Lobsiger and Cleveland, 2007; Pavese et al., 2006). Thus, we determined whether downregulation of microglial activation by SOSC might produce alteration in mRNA expression of representative pro-inflammatory and anti-inflammatory mediators by RT PCR analysis (Figures 6A–H). mRNA expression levels of pro-inflammatory cytokines (IL-1β and IL-6) and enzymes (COX-2 and iNOS) were enhanced in the 3-NPA group than in the sham group with the following results: IL-1β increased by 165.6%, IL-6 increased by 464.2%, COX-2 increased by 197.5%, and iNOS increased by 238.6% (Figures 6A–E). However, SOSC significantly inhibited these increases induced by 3-NPA with the following results: IL-1β inhibited by 113.4%, IL-6 inhibited by 310.0%, COX-2 inhibited by 134.4%, and iNOS inhibited by 147.2% compared to those in the 3-NPA group (Figures 6A–E). On the other hand, SOSC significantly enhanced mRNA expression levels of anti-inflammatory cytokines (IL-10 and TGF-β) and anti-inflammatory agents (arginase-1) than in the 3-NPA group with the following results: IL-10 increased by 717.6%, TGF-β increased by 159.7%, and arginase-1 increased by 128.6% (Figure 6A, F–H). Additionally, to investigate whether the positive regulatory effects of SOSC on the mRNA expression levels of pro- and anti-inflammatory mediators are reflected at the protein expression level, Western blot analysis was performed for each antibody. As expected, SOSC significantly inhibited the 3-NPA-induced increase in the protein expression levels of pro-inflammatory mediators (IL-1β, IL-6, COX-2, and iNOS) (Figure 6I–M). Conversely, it significantly elevated the protein expression levels of anti-inflammatory mediators (IL-10, TGF-β, and arginase-1) compared to the 3-NPA group (Figure 6I, N–P).

MAPKs and NF-κB signaling pathways play critical roles in neuroinflammatory and neuropathological mechanisms of neurodegenerative disorders such as HD (Cai et al., 2022; Zhang et al., 2023). Thus, we determined whether SOSC could regulate these pathways in the striatum after 3-NPA-intoxication (Figures 7A–E). Expression levels of p-ERK, p-JNK, and p-p38 MAPKs protein were clearly increased by 213.5%, 186.2%, and 115.2%, respectively, in the striatum following the last (4^th) 3-NPA-intoxication compared to those in the sham group. However, SOSC significantly decreased expression levels of p-ERK, p-JNK, and p-p38 MAPKs proteins by 123.7%, 124.2%, and 62.6%, respectively (Figures 7A–D). In additional, expression levels of p-IκB and p-NF-κB protein were distinguishably upregulated by 140.7% and 138.4%, respectively, in the striatum after the last (4^th) 3-NPA-intoxication compared to those in the sham group. However, SOSC significantly downregulated their expression level in by 94.0% and 98.3%, respectively (Figures 7A, E, F). These findings suggest that SOSC could inhibit inflammatory response and striatal toxicity after 3-NPA-intoxication by inhibiting MAPKs and NF-κB signaling pathways in the striatum.

Oxidative stress has been implicated in the pathogenesis of many neurodegenerative diseases including HD (Teixeira et al., 2019). Oxidative stress leading to free radical attack on neural cells contributes calamitous role to neurodegeneration (Teixeira et al., 2019). Thus, we examined whether administration with SOSC might reduce the generation of oxidative stress in the striatum after 3-NPA-intoxication. Protein expression of 4-hydroxynonenal (4-HNE), a marker for reactive oxygen species (ROS), was clearly enhanced in the striatum of the 3-NPA group (261.5 ± 34.3) compared to that of the sham group (103.9 ± 11.6), whereas such enhanced expression was significantly reduced in the striatum of the 3-NPA + SOSC (300 mg/kg) group (156.7 ± 30.0) compared to that of the 3-NPA group (Figures 8A, B). The ameliorating effect of SOSC on 4-HNE was closely related to a downregulated intensity of MitoSOX, a mitochondrial superoxide indicator, in the striatum of 3-NPA + SOSC (300 mg/kg) group (Figure 8E). On the other side, the Nrf2/heme oxygenase 1 (HO-1) signaling pathway governs gene expression of endogenous antioxidant synthesis and ROS-eliminating enzymes as an antioxidant defense mechanism for protecting brain cells against abnormal ROS levels (Kasai et al., 2020). Thus, we further examined whether SOSC might stimulate the Nrf2/HO-1 pathway by Western blot assay for Nrf2 (a transcription factor for antioxidant responses) and HO-1 (a representative product of the Nrf2 pathway and antioxidant enzyme) (Figure 8A). Administration with SOSC (300 mg/kg) significantly stimulated Nrf2 and produced HO-1 protein by 147.5% and 159.7%, respectively, in the striatum after 3-NPA-intoxication compared to those of 3-NPA group without administration with SOSC (74.8 ± 7.5 and 82.4 ± 5.1, respectively) (Figures 8A, C, D, F). Stimulated effects of SOSC on Nrf2 and HO-1 proteins were closely connected with enhanced nuclear translocation of Nrf2 and enhanced cytoplasmic expression of HO-1 in the striatum of the 3-NPA + SOSC (300 mg/kg) group compared to those of the 3-NPA group without administration with SOSC (Figures 8G, H). These results suggest that SOSC might have improved striatal neurodegeneration by inhibiting ROS generation and stabilizing the Nrf2/HO-1 antioxidant signaling pathway in the brains of the 3-NPA group.

SOSC ameliorated 3-NPA-induced HD-like symptoms and neuropathology through its anti-inflammatory and antioxidant mechanisms by inhibiting microglial activation in the striatum from 3-NPA-intoxicated HD model (Figures 3–8). According to the MTT assay, the cell viabilities by Schizandrin were not significantly affected by at least 80 μM (Figure 9A). To further understand SOSC’s action mechanism, cultured BV2 cells (cell line for microglia) were stimulated with schizandrin (a main component of SOSC) (40, 60, and 80 μM) at 1 h before 3-NPA stimulation. As a result, schizandrin treatment significantly decreased protein expression levels of Iba-1 (a representative marker of microglial activation), representative proinflammatory agents (IL-1β, IL-6, TNF-α, COX-2, and iNOS), and p-NF-κB (a representative proinflammatory pathway), but significantly enhanced Nrf2 in a dose-dependent manner after 3-NPA treatment (Figures 9B–K). Subsequently, to examine whether conditioned medium from schizandrin/3-NPA-treated BV2 cells (CM-Sch-3-NPA) could reduce neurodegeneration (apoptosis) of cultured SH-SY5Y cells (a neuroblastoma cell line) compared to conditioned medium from 3-NPA-treated BV2 cells (CM-3-NPA), cells were treated with CM-Sch-3-NPA or CM-3-NPA. As a result, CM-Sch/3-NPA clearly increased protein expression levels of NeuN (a marker for neuronal cells) but and reduced cleaved caspases-3 (a marker for apoptosis), in a dose-dependent manner compared to treatment with CM-3-NPA after 3-NPA treatment (Figure 9L–O). These results suggest that schizandrin may inhibit neuronal death and apoptosis of 3-NPA-induced SH-SY5Y cells through its anti-inflammatory and antioxidant activities in 3-NPA-induced BV2 cells.